Research programme: cancer therapeutics - SelvitaAlternative Names: GCN2 kinase inhibitor - Selvita; General control non-repressed kinase inhibitor - Selvita; Serine hydroxymethyltransferase 2 inhibitors - Sevita; SHMT2 inhibitors - Selvita; Stimulator of interferon genes agonist - Selvita; STING agonists - Selvita
Latest Information Update: 19 Dec 2016
At a glance
- Originator Selvita
- Class Antineoplastics; Small molecules
- Mechanism of Action Hydroxymethyl and formyl transferase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Dec 2016 Preclinical trials in Cancer in Poland (unspecified route) before December 2016